2 This is in contradistinction to a much larger and highly significant 45% reduction in kidney disease progression in a pooled analysis of the 3 large broadly inclusive cardiovascular outcome trials of SGLT2 inhibitors. 12 Adverse kidney events were not discussed in these meta-analyses with either GLP-1 receptor agonists or SGLT2 inhibitors. 2 , 12 However, in the Can
1
—
—